Hemogenyx Pharmaceuticals stock jumps after third patient in CAR-T AML trial shows safety and early efficacy

Hemogenyx Pharmaceuticals PLC (LSE: HEMO) saw its shares surge by more than 24 percent on 17 September 2025, closing at 1,535 GBX, after the company announced encouraging clinical trial results for its HG-CT-1 CAR-T therapy targeting relapsed and refractory acute myeloid leukemia. The move reflects heightened investor optimism as the company achieved an important early milestone in its Phase I program, with the third patient successfully treated and initial safety criteria met. The announcement pushed Hemogenyx stock near its 52-week highs and reignited speculation about its place in the competitive and high-stakes CAR-T therapy landscape.

Why did Hemogenyx Pharmaceuticals stock surge more than 24 percent in a single trading session?

The sharp rally in Hemogenyx shares followed confirmation that the third patient enrolled in the Phase I study of HG-CT-1 had responded positively, with the therapy showing signs of both safety and efficacy. According to the company, acute myeloid leukemia cells were undetectable in this patient using standard testing methods following infusion of the CAR-T product. Importantly, the therapy was also reported to be well tolerated, reinforcing confidence in its safety profile. The London Stock Exchange data showed that Hemogenyx opened trading at 1,480 GBX and reached a high of 1,790 GBX during the day before closing at 1,535 GBX, up 302.5 points or 24.54 percent compared with the prior session. For investors, such a move signals not just speculative enthusiasm but also renewed conviction in the scientific credibility of Hemogenyx’s program.

What makes HG-CT-1 CAR-T therapy different from other approaches in relapsed and refractory AML?

Hemogenyx’s HG-CT-1, also referred to as HEMO-CAR-T, is designed to target the FLT3 receptor, a cell-surface protein that is overexpressed in many cases of acute myeloid leukemia. FLT3 mutations are associated with more aggressive disease progression and poorer prognoses, making the receptor an attractive therapeutic target. Unlike approved CAR-T therapies, which primarily address B-cell malignancies such as acute lymphoblastic leukemia or diffuse large B-cell lymphoma, Hemogenyx is among a small group of companies pursuing CAR-T solutions in AML. The Phase I trial of HG-CT-1 is structured as a dose-escalation study. While its primary endpoint is safety and tolerability, it also incorporates secondary measures such as AML-specific response rates, progression-free survival, overall survival, and duration of response in patients demonstrating clinical benefit. These are standard benchmarks in early oncology trials and help determine whether a therapy is likely to justify progression into later-phase studies.

How significant is the treatment of a third patient in shaping investor and clinical sentiment?

The fact that three patients have now been treated at the lowest dose level, with all meeting predefined safety criteria, is crucial for Hemogenyx. In early-stage biotech development, small numbers of patients can move markets if they offer proof-of-concept signals. For HG-CT-1, the third patient’s outcome is important because it not only reinforces the safety profile but also shows early evidence of efficacy in the form of undetectable AML cells. While this does not prove long-term remission or guarantee success in a larger trial, it provides a foundation of clinical credibility. Safety data from these first three patients will be submitted to an independent Data Safety Monitoring Board, which will then decide whether dose escalation to higher levels can proceed. Approval to move forward would be viewed positively by investors and would likely serve as the next major catalyst for the stock.

What are the trading metrics and how do they compare with recent performance?

At the close of trading on 17 September, Hemogenyx shares were priced at 1,535 GBX, with the day’s range stretching from a low of 1,355 GBX to a high of 1,790 GBX. The bid-offer spread stood at 1,475 to 1,595 GBX, reflecting heightened liquidity and trading volume. For context, Hemogenyx stock has been highly volatile, with a 52-week range spanning from as low as 124 GBX to levels now nearing 1,800 GBX. This volatility is typical of early-stage biotech firms listed on the London Stock Exchange, where investor sentiment can swing sharply based on clinical updates. With the latest surge, Hemogenyx is trading near the top of its one-year range, underlining the bullish momentum but also highlighting the risks if expectations are not met in future trial readouts.

Why is AML such a challenging disease area, and how does Hemogenyx’s approach fit into the wider landscape?

Acute myeloid leukemia is one of the most aggressive forms of blood cancer, particularly in relapsed or refractory settings where standard treatments such as chemotherapy and stem cell transplants have failed. The prognosis for patients in this category remains poor, with limited therapeutic options and survival rates often measured in months rather than years. This is one reason why AML is considered a frontier challenge for cell therapy developers. The majority of CAR-T therapies approved to date are for B-cell malignancies, where targets such as CD19 have provided a clear pathway for selective tumor killing. AML poses additional difficulties because many of the antigens expressed on leukemia cells are also found on normal hematopoietic cells, increasing the risk of severe toxicity. Hemogenyx’s focus on FLT3 is designed to overcome some of these hurdles by exploiting a mutation-associated target that is disproportionately expressed on AML blasts. If successful, HG-CT-1 could represent a breakthrough in a disease area that has long resisted effective treatment innovation.

What risks remain for Hemogenyx despite the positive market response?

Despite the optimism, Hemogenyx remains at a very early stage in the clinical development process. Phase I trials are designed primarily to establish safety, not definitive efficacy. While early indications are promising, they are based on only three patients, which is far too small a sample to draw generalizable conclusions. The challenge for the company will be to reproduce these results across larger patient cohorts and at higher doses. Manufacturing and scalability present additional hurdles. CAR-T therapies are notoriously difficult and expensive to produce, requiring individualized patient cell engineering, strict quality control, and robust logistics. Hemogenyx has attempted to address these challenges by entering into a partnership with Made Scientific, a U.S.-based cell therapy contract manufacturer, to advance the technology transfer and scale-up of HG-CT-1. Nevertheless, successful execution will be critical, as supply chain and cost issues have hampered even larger, better-funded biotech firms in the past.

How are investors and institutions reacting to the latest update?

The stock market’s 24 percent jump suggests strong speculative buying interest, but the sustainability of this momentum will depend on institutional investor confidence. Small-cap biotech stocks often attract retail traders seeking quick gains, but the entry of larger investors typically depends on reproducibility of trial results, evidence of scalability, and clear regulatory pathways. While no major analyst upgrades were reported immediately following the announcement, the broader investor mood is clearly bullish. The move also reflects the appetite for high-risk, high-reward biotech plays on the London Stock Exchange, where clinical-stage companies can swing dramatically in value on the back of incremental trial updates. Investors will likely adopt a cautious stance in the medium term, balancing the potential for transformational breakthroughs against the very real risk of setbacks.

What milestones should investors watch for in the coming quarters?

The immediate milestone to watch is the decision by the Data Safety Monitoring Board on whether Hemogenyx can escalate to higher doses in its Phase I trial. Positive news on dose escalation would open the door to testing HG-CT-1’s efficacy more robustly, which could provide a more reliable read on clinical potential. Beyond that, the key secondary endpoints, including progression-free survival, duration of response, and overall survival, will become increasingly important as data matures. Manufacturing progress through the Made Scientific partnership will also be closely monitored, as reproducible and scalable CAR-T production is essential for both clinical development and eventual commercialization. On the corporate side, Hemogenyx will need to ensure sufficient funding to advance its program, either through capital raises, strategic partnerships, or licensing agreements. Any sign of cash shortfalls could temper investor enthusiasm and weigh on the stock price, even if clinical data continues to be encouraging.

What is the future outlook for Hemogenyx Pharmaceuticals in the CAR-T space?

The successful treatment of a third patient in the HG-CT-1 trial provides Hemogenyx with much-needed momentum, both scientifically and financially. In a sector where many early-stage companies struggle to translate preclinical promise into human efficacy, Hemogenyx has shown a tangible signal that its CAR-T approach may work in relapsed and refractory AML. If ongoing and future patients continue to demonstrate safety and efficacy, Hemogenyx could emerge as a credible competitor in the AML treatment market, a space where very few therapies have succeeded. The company’s ability to scale its manufacturing and navigate the regulatory process will be equally important in determining its long-term success. For now, Hemogenyx remains a speculative investment but one that has captured the attention of both retail traders and institutional watchers. The next several quarters will be pivotal in deciding whether this momentum can translate into durable value creation.